WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2023)
Top general drug manufacturer stocks in 2023 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
BMY
BRISTOL MYERS SQUIBB CO
$122.80B$45.19B$18.65B$7.96B$3.78-4.15%15.91%24.34%72.15%2023-10-26
HZNP
HORIZON THERAPEUTICS PUBLIC LTD CO
$26.47B$3.64B$901.54M$438.00M$1.92-4.42%27.71%-42.86%N/A2023-11-08
GILD
GILEAD SCIENCES INC
$94.47B$27.38B$10.68B$5.48B$4.39-0.48%3.37%33.03%20.89%2023-10-25
PFE
PFIZER INC
$189.82B$77.94B$28.47B$21.47B$3.81-23.04%7.92%-27.01%0.05%2023-10-31
SNY
SANOFI
$137.99B$51.84B$16.76B$9.68B$3.8714.58%4.01%35.24%17.96%2023-10-27
AZN
ASTRAZENECA PLC
$210.54B$44.49B$13.13B$6.16B$1.991.02%14.77%N/A13.53%2023-11-09
GSK
GSK PLC
$77.07B$38.10B$25.25B$20.04B$9.939.44%-1.49%248.94%53.62%2023-11-01
LLY
ELI LILLY & CO
$540.76B$29.52B$8.75B$6.50B$7.211.53%8.68%14.63%N/A2023-11-02
BIIB
BIOGEN INC
$37.73B$9.97B$3.71B$2.66B$18.48-6.23%-4.98%31.62%5.48%2023-10-23
AMGN
AMGEN INC
$145.20B$26.58B$14.82B$7.98B$14.930.75%2.77%26.20%31.90%2023-11-01
ABBV
ABBVIE INC
$271.13B$56.02B$21.07B$8.69B$4.88-2.31%12.60%-31.17%3.80%2023-10-26
MRK
MERCK & CO INC
$272.30B$58.31B$10.14B$3.11B$1.222.00%7.16%-81.40%19.06%2023-10-26
AMRN
AMARIN CORP PLC
$388.33M$346.27M-$44.75M-$38.30M-$0.08-27.19%11.85%N/AN/A2023-10-27
JNJ
JOHNSON & JOHNSON
$423.40B$97.77B$24.11B$13.05B$4.992.29%3.92%-28.61%56.59%2023-10-17
NVS
NOVARTIS AG
$214.23B$53.07B$22.06B$7.65B$3.620.54%4.82%-64.79%-9.46%2023-10-24
OGN
ORGANON & CO
$4.84B$6.17B$1.60B$754.00M$2.96-2.94%N/A-32.11%N/A2023-11-01
GRFS
GRIFOLS SA
$6.63B$6.59B$1.31B$226.39M$0.3415.08%4.47%3.77%-22.28%2023-11-02
SCLX
SCILEX HOLDING CO
$253.39M$46.46M-$46.30M-$53.79M-$0.4448.33%N/AN/AN/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Sep 2023?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 57, which is 16 points higher than the general drug manufacturer industry average of 41. It passed 21 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -15.7% over the past year, underperforming other general drug manufacturer stocks by -45 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $70.75, an upside of 20.36% from Bristol Myers Squibb Co's current stock price of $58.78.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 41.67% have issued a hold, while 8.33% have issued a Sell rating, and 8.33% have issued a Strong Sell.

2. Horizon Therapeutics Public Co (NASDAQ:HZNP)


Horizon Therapeutics Public Co (NASDAQ:HZNP) is the second best general drug manufacturer stock with a Zen Score of 54, which is 13 points higher than the general drug manufacturer industry average of 41. It passed 18 out of 33 due diligence checks and has strong fundamentals. Horizon Therapeutics Public Co has seen its stock return 82.1% over the past year, overperforming other general drug manufacturer stocks by 52 percentage points.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) is the third best general drug manufacturer stock with a Zen Score of 53, which is 12 points higher than the general drug manufacturer industry average of 41. It passed 19 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 17.4% over the past year, underperforming other general drug manufacturer stocks by -12 percentage points.

Gilead Sciences has an average 1 year price target of $87.67, an upside of 15.63% from Gilead Sciences's current stock price of $75.82.

Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Gilead Sciences, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 44.44% have issued a hold, while 11.11% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 4.85%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.06%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 42.8% indicates that its dividend yield is sustainable for the long-term.

2. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 3.93%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.06%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 67.4% indicates that its dividend yield is sustainable for the long-term.

3. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 3.83%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.06%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 59.5% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.42% in the last day, and down -0.31% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Grifols Sa's stock has gained 14.2% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -15 percentage points.

2. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Organon & Co has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -30.7% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -60 percentage points.

3. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Sanofi's stock has gained 38.21% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 9 percentage points.

Are general drug manufacturer stocks a good buy now?

46.15% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 8.45% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 41.36x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.